Compare TOL & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | NBIX |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 15.5B |
| IPO Year | 1994 | 1996 |
| Metric | TOL | NBIX |
|---|---|---|
| Price | $134.30 | $151.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 22 |
| Target Price | $164.44 | ★ $180.91 |
| AVG Volume (30 Days) | 656.9K | ★ 901.4K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | ★ 7.87 | 3.30 |
| Revenue | ★ $7,143,258,000.00 | $161,626,000.00 |
| Revenue This Year | N/A | $24.73 |
| Revenue Next Year | $6.01 | $13.14 |
| P/E Ratio | ★ $17.13 | $45.73 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $123.15 | $122.14 |
| 52 Week High | $168.36 | $186.12 |
| Indicator | TOL | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 38.20 |
| Support Level | $130.33 | $125.85 |
| Resistance Level | $153.78 | $161.00 |
| Average True Range (ATR) | 3.25 | 4.01 |
| MACD | -0.67 | -0.12 |
| Stochastic Oscillator | 22.35 | 14.97 |
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.